Rosner Daniel, Clark Jason
Fixed Phage Ltd., Glasgow G20 0SP, UK.
Pharmaceuticals (Basel). 2021 Apr 13;14(4):359. doi: 10.3390/ph14040359.
The emergence of antibiotic-resistant pathogens is becoming increasingly problematic in the treatment of bacterial diseases. This has led to bacteriophages receiving increased attention as an alternative form of treatment. Phages are effective at targeting and killing bacterial strains of interest and have yielded encouraging results when administered as part of a tailored treatment to severely ill patients as a last resort. Despite this, success in clinical trials has not always been as forthcoming, with several high-profile trials failing to demonstrate the efficacy of phage preparations in curing diseases of interest. Whilst this may be in part due to reasons surrounding poor phage selection and a lack of understanding of the underlying disease, there is growing consensus that future success in clinical trials will depend on effective delivery of phage therapeutics to the area of infection. This can be achieved using bacteriophage formulations instead of purely liquid preparations. Several encapsulation-based strategies can be applied to produce phage formulations and encouraging results have been observed with respect to efficacy as well as long term phage stability. Immobilization-based approaches have generally been neglected for the production of phage therapeutics but could also offer a viable alternative.
抗生素耐药性病原体的出现,在细菌性疾病的治疗中愈发成为一个难题。这使得噬菌体作为一种替代治疗形式,受到了越来越多的关注。噬菌体能够有效地靶向并杀死目标细菌菌株,作为针对重症患者的定制化治疗的最后手段使用时,已取得了令人鼓舞的成果。尽管如此,临床试验并非总能取得成功,一些备受瞩目的试验未能证明噬菌体制剂在治愈相关疾病方面的疗效。虽然这部分可能是由于噬菌体选择不当以及对潜在疾病缺乏了解等原因,但越来越多的人达成共识,即未来临床试验的成功将取决于噬菌体疗法能否有效递送至感染部位。这可以通过使用噬菌体制剂而非单纯的液体制剂来实现。几种基于封装的策略可用于生产噬菌体制剂,并且在疗效以及噬菌体长期稳定性方面已观察到令人鼓舞的结果。基于固定化的方法在噬菌体疗法的生产中通常被忽视,但也可能提供一种可行的替代方案。